Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,819 across all filing types
Latest filing 2023-01-24 Earnings Release
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
Earnings Release Classification · 1% confidence The document is a short company announcement (under 5,000 characters of core text) that provides a specific financial highlight (DARZALEX net sales for 2022) and explicitly includes an 'Attachment' link to the full report. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the full financial report itself. FY 2022
2023-01-24 Danish
6-K
Foreign Filer Report
2023-01-19 English
Director's Dealing 2023
Director's Dealing Classification · 1% confidence The document is titled "Correction to Company Announcement No. 1 of January 3, 2023" and explicitly references transactions made by managerial employees and closely associated persons regarding shares in Genmab A/S, citing Article 19 of Regulation No. 596/2014 (Market Abuse Regulation). This type of disclosure, concerning insider trading or transactions by management/directors, directly corresponds to the 'Director's Dealing' category. Although it is a correction to a previous announcement, the core subject matter is insider transactions, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains the substantive details of the correction itself. The classification 'DIRS' (Director's Dealing) is the most appropriate fit.
2023-01-19 English
Correction to Company Announcement No. 1 of January 3, 2023
Director's Dealing Classification · 1% confidence The document is a formal notification regarding a correction to a previous announcement about share transactions by a member of the Board of Directors (Mijke Zachariasse). It explicitly references Regulation No. 596/2014 on Market Abuse, which governs the disclosure of transactions by persons discharging managerial responsibilities. This falls squarely under the definition of 'Director's Dealing' (DIRS), as it reports personal share transactions by a company director.
2023-01-19 English
6-K
Foreign Filer Report
2023-01-03 English
Director's Dealing 2023
Director's Dealing Classification · 1% confidence The document is titled 'Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons' and explicitly states it discloses transactions made by managerial employees in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse. This regulation mandates the disclosure of insider trading or transactions by persons discharging managerial responsibilities (PDMRs). This directly corresponds to the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document is a formal announcement of these transactions, not a general regulatory filing (RNS) or a report on remuneration (DEF 14A).
2023-01-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.